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L6PEZ-SAmDO. S., E. RODRfGUEZ-MARTtiN, A. MARfiN-ESPINOSA AND E. ARILLA. Effect ofphenylephtine and 
prazosin on the somatostutinergic system in the rat frontopariejal cortex. PEPTIDES 16(8) 1453- 1459, 1995.-Somatostatin 
(SS) and noradrenaltne (NA) are distributed in the rat cerebral cortex. and seizure activity is one of the aspects of behavior affected 
by both neurotransmitters. Due to the possible interaction between both neurotransmitter systems, we studied whether phenyl- 
phrine, an a,-adrenoceptor agonist, and prazosin, an a,-adrenoceptor antagonist. can modulate SS-like immunoreactivity (SS-LI) 
levels, binding of [“%][Tyr”]SS to its specific receptors, the ability of SS to inhibit adenylate cyclase (AC) activity, and the 
guanine nucleotide binding regulatory protein G, and G,, in the Sprague-Dawley rat frontoparietal cortex. An IP dose of 2 or 4 
mg/kg of phenylephrine injected 7 h before decapitation decreased the number of SS receptors and increased the apparent affinity 
in frontoparietal cortex membranes. An IP dose of 20 or 25 mg/kg of prazosin administered 8 h before decapitation increased the 
number of SS receptors and decreased their apparent affinity. The administration of prazosin before the phenylephrine injection 
prevented the phenylephrine-induced changes in SS binding. The addition of phenylephrine and/or prazosin IO-’ M to the incu- 
bation medium changed neither the number nor the affinity of the SS receptors in the frontoparietal cortex membranes. Phenyl- 
ephrine or prazosin affected neither SS-LI content nor the basal or forskolin (FK)-stimulated AC activities in the frontoparietal 
cortex. In addition, SS caused an equal inhibition of AC activity in frontoparietal cortex membranes of phenylephrine- and prazosin- 
treated rats compared with the respective control group. Finally, phenylephrine and prazosin did not vary the pertussis toxin (FTX)- 
catalyzed ADP ribosylation of G,- and/or G,-proteins. These results suggest that the above-mentioned changes are related to the 
phenylephrine activation of al-adrenoceptors or to the blocking of these receptors by prazosin. In addition. these data provide 
further support for a functional interrelationship between the c~,-adrenergic and somatostatinergic systems in the rat frontoparietal 
cortex. 
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SOMATOSTATIN (SS), iirst identified as a tetradecapeptide in 
the hypothalamus (8), is one of the most highly concentrated and 
widely distributed peptides in the mammalian nervous system 
(17,26,46). In the central nervous system (CNS), SS is a neuro- 
transmitter that regulates neuronal activity and the release of 
other transmitters (12,58). Significant amounts of SS have been 
detected in the cerebral cortex (15). In addition, cerebral cortex 
membranes contain one of the largest concentrations of SS re- 
ceptors (29,37,40,52,57,6(l). Noradrenergic fibers originating in 
the locus coeruleus are also widely distributed in the cerebral 
cortex (9,24,32). In the rat neocortex, (Y, adrenoceptors have been 
localized by autoradiography to lamina I and lamina Va and Vc, 
sparing the layer Vb pyramidal cells (27). Somatostatinergic and 
noradrenergic neurotransmission modulate neuronal firing 
(15,49). Seizure activity is one of the aspects of behavior affected 
by SS. Applied to rats, SS causes general tonic-clonic seizures 
that are mediated through local depression of EEG activities and/ 
or epileptic spiking in the cortex, hippocampus, and striatum 
(23). The central noradrenergic system also plays an important 
role in the regulation of cortical neuronal excitability (49). Drugs 
or lesions that deplete brain stores of noradrenaline (NA) are 
known to facilitate seizures in many species, including humans 
(11). The highly selective a, agonist SE 587, which easily pen- 
etrates the blood-brain barrier, displays significant anticonvul- 
sant activity in both epileptic gerbils (33) and in rats with spon- 
taneous petit mal-like seizures (39). 
The present study was undertaken to determine whether the 
a,-adrenergic system can modulate the somatostatinergic system 
in the rat frontoptietal cortex. Therefore, we used phenyle- 
phrine, an cr,-adrenoceptor agonist, and prazosin, an rw,-adreno- 
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1453 
1454 LOPEZ-SABUDO ET AL. 
ceptor antagonist, to evaluate their effects on the [ “‘I][Tyr’ ‘]SS 
binding to its specific receptors, SS-modulated adenylate cyclase 
(AC) activity, expression of the (Y subunit of the guanine nucle- 
otide regulatory proteins Gi and G,, and SS-like immunoreactiv- 
ity (SS-LI) concentration in the rat frontoparietal cortex. 
METHOD 
Chemicals 
Synthetic [Tyr”]SS and SS tetradecapeptide were purchased 
from Universal Biologicals Ltd (Cambridge, UK); phenylephrine 
hydrochloride, bacitracin, phenyhnethylsulfonyl fluoride (PMSF), 
3-isobutyl-1-methylxanthine (IBMX), pertussis toxin (PTX), bo- 
vine serum albumin (BSA), GTP, forskolin (FK), and prestained 
protein markers and other reagents for sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) were supplied 
by Sigma Quimica (Madrid, Spain); prazosin hydrochloride 
(Minipres) from Pfizer (Madrid, Spain); and carrier-free Na’*‘I 
(IMS 30, 100 mCi/ml) from the Radiochemical Centre (Amer- 
sham, UK). [Tyr”]SS was radioiodinated by the chloramine-T 
method (21). The tracer was purified on a Sephadex G-25 coarse 
column (1 x lOO), which had been equilibrated with 0.1 M acetic 
acid, containing BSA 0.1% (w/v). Specific tracer radioactivity 
was about 600 Wmmol. The rabbit antibody used in the radio- 
immunoassay technique was purchased from the Radiochemical 
Centre. This antiserum was raised in rabbits against SS-14 con- 
jugated to BSA and is specific for SS, but because SS-14 also 
constitutes the C-terminal portions of both SS-25 and SS-28, the 
antiserum does not distinguish between these three forms. Cross- 
reactivity with other peptides was less than 0.5%. Cross-reaction 
with several SS analogues demonstrated that neither the N-ter- 
minal glycine nor the C-terminal cysteine residue is required for 
antibody binding, suggesting that the antigen site is directed to- 
wards the central part of the molecule containing the tryptophan 
residue. The binding of SS-14 to its antibody does not depend 
on an intact disulfide bond in the molecule, because breaking of 
the disulfide bond by reaction with 0.1% mercaptoethanol (boil- 
ing water bath, 5 min) did not change peptide immunoreactivity. 
Experimental Animals 
The animals used in this study were Sprague-Dawley rats 
(n = 60) weighing between 200 and 250 g. Rats were maintained 
on a 12-h light/dark cycle (0700- 1900 h) and allowed free access 
to food. Phenylephrine (0.5,2, and 4 mg/kg> and prazosin (5,20, 
and 25 mg/kg) were dissolved in distilled water or propylene 
glycol 25%, respectively, as previously described (5,6). Fresh 
solutions were prepared every day just prior to administration. 
Drugs were diluted such that injections were in volumes of 2.0 
ml/rat and were administered IP 7 h (phenylephrine) or 8 h (pra- 
zosin) prior to assay. In another experimental group, prazosin (20 
mg/kg, IP) was administered 1 h before phenylephrine (2 mg/kg, 
IP). Control animals for each group cited were injected with 
equivalent volumes of distilled water, propylene glycol 25%, or 
propylene glycol 25% plus distilled water according to whether 
the corresponding experimental group was to be injected with 
phenylephrine, prazosin, or prazosin plus phenylephrine, respec- 
tively. Drug doses were selected according to the effective dose 
reported in previous studies (5,6). Rats were killed by decapita- 
tion at 7 or 8 h after the last injection, as appropriate. The brain 
was rapidly removed and the frontoparietal cortex was dissected 
over ice according to the method of Glowinski and Iversen (20). 
Tissue Extraction and SS Radioimmunoassay 
For SS-LI measurements, the frontoparietal cortex was rap- 
idly homogenized using a Brinkman polytron (setting 5, 30 s), 
in 1 ml 2 M acetic acid. Extracts were boiled for 5 min in a water 
bath, chilled in ice, and aliquots (100 ~1) were removed for pro- 
tein determination (34). Subsequently, homogenates were cen- 
trifuged at 15,000 x g for 15 min at 4”C, and the supematant 
was neutralized with 2 M NaOH. Extracts were immediately 
stored at -70°C until assay. SS-LI level was determined in tissue 
extracts by a modified radioimmunoassay method (45), with a 
sensitivity limit of 10 pg/ml. Incubation tubes prepared in dupli- 
cate contained lOO+l samples of unknown or standard solutions 
of O-500 pg cyclic SS tetradecapeptide diluted in phosphate buf- 
fer (0.05 M, pH 7.2 containing 0.3% BSA, 0.01 M EDTA), 200 
~1 of appropriately diluted antiserum, 100 ~1 of freshly prepared 
[‘*‘I][Tyr”]SS diluted in buffer to give 6000 cpm/assay tube 
(equivalent to 5- 10 pg), and enough buffer to give a final volume 
of 0.8 ml. All reagents as well as the assay tubes were kept chilled 
on ice before incubation at 4°C for 48 h. Separation of bound and 
free hormone was accomplished by the addition of 1 ml dextran- 
coated charcoal (dextran T70: 0.2% w/v, Pharmacia, Uppsala, 
Sweden; charcoal: Norit A 2% w/v, Serva, Feinbiochemica, Hei- 
delberg, Germany). Dilution curve for this brain area was parallel 
to the standard curve. The intra- and interassay variation coeffi- 
cients were 6.8% and 8.1%, respectively. 
Binding Assay for Membrane Preparations 
Frontoparietal cortex membranes were prepared as described 
by Reubi et al. (52). Proteins were assayed by the method of 
Lowry et al. (34), with BSA as a standard. Specific SS binding 
was measured according to the modified method of Czemik and 
Petrack (13). The membranes (0.15 mg protein/ml) were incu- 
bated in 0.25 ml of a medium containing 50 mM Tris-HCl buffer 
(pH 7.5), 5 mM MgC12, 0.2% (w/v) BSA, and 0.1 mg/ml baci- 
tracin with 250 pM [“‘I][Tyr”]SS either in the absence or in the 
presence of 0.01 - 10 nM unlabeled SS. After 60-min incubation 
at 3O”C, membrane-bound peptide was isolated by centrifugation 
at 11,000 x g for 2 min, and radioactivity was determined in a 
Kontron gamma counter. Specific binding was defined as the 
difference in the amount of radioligand bound in the absence and 
presence of lo-’ M SS. 
Evaluation of Radiolabeled Peptide Degradation 
To determine the extent of tracer degradation during incuba- 
tion, we measured the ability of preincubated peptide to bind to 
fresh frontoparietal cortex membranes as previously described 
(1). Briefly, [‘*‘I][Tyr”]SS (250 PM) was incubated with mem- 
branes from rat frontoparietal cortex (0.15 mg protein/ml) for 60 
min at 30°C. After this preincubation, aliquots of the medium 
were added to fresh membranes and incubated for an additional 
60 min at 30°C. The fraction of the added radiolabeled peptide, 
which was specifically bound during the second incubation, was 
measured and expressed as a percentage of the binding that had 
been obtained in control experiments performed in the absence 
of membranes during the preincubation period. 
Adenylate Cyclase Assay 
The AC activity was measured as previously reported (25) 
with minor modifications (22). Briefly, rat frontoparietal cortex 
membranes (0.06 mg/ml) were incubated with 1.5 mM ATP, 5 
n&f MgSO,, 10 ,u&f GTP, an ATP-regenerating system (7.5 mg/ 
ml creatine phosphate and 1 mg/ml creatine kinase), 1 mM 
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FIG. 1. Effects of in vivo phenylephrine administration on somatostatin 
(SS) binding to frontoparietal cortex membranes. Left panel: competitive 
inhibition of specific [‘rSI][Tyr”]SS binding by unlabeled SS to fronto- 
parietal cortex membranes. klembranes (0.15 mg protein/ml) were in- 
cubated for 60 min at 30°C in the presence of 250 pM [“‘I][Tyr”]SS 
and increasing concentrations of native peptide. Points correspond to 
values for the animals in the control group (0) and phenylephrine-treated 
group (0). Each point is the mean + SEM of five replicate experiments. 
Right panel: Scatchard analysis of the same data. 
IBMX, 0.1 mkf PMSF, 1 mg/ml bacitracin, 1 m&f EDTA, and 
test substances ( 10m4 M SS or lo-’ M FK) in 0.1 ml of 0.025 M 
triethanolamine-HCl buffer (pH 7.4). After 15min incubation at 
3O”C, the reaction was stopped by heating the mixture for 3 min. 
After refrigeration, 0.2 ml of an alumina slurry (0.75 g/ml in 
triethanolamine-HCl buffer, pH 7.4) was added and the suspen- 
sion was centrifuged. The supematant was taken to assay the 
cyclic AMP (CAMP) by using the method of Gilman (19). The 
SS concentration used was the one that is known to inhibit rat 
(42,54) and human (18) brain AC. FK was used at a concentration 
of 10e5 M, which primarily stimulates the catalytic subunit of 
AC (55). 
Pertussis Toxin-Catalyzed ADP Ribosylation 
The PTX-catalyzed ADP ribosylation was carried out as pre- 
viously reported (7). After PTX activation, membranes (0.8 mg 
of protein/ml) were incub,ated with PTX (16 pg/ml) in 100 mM 
Tris-Cl buffer (pH 8.0), containing 10 mM thymidine, 1 mM 
ATP, 100 /JM GTP, 2.51 rnkf MgC&, 1 mkl EDTA, 1 /&f 
[‘*PINAD+ (30 Wmmol), and an ATP-regenerating system. Af- 
ter 30 min at 30°C the reaction was stopped by addition of 1 ml 
of ice-cold 100 miU Tris-HCl buffer (pH 8.0), sedimented by 
centrifugation for 10 min at 30,000 X g and the pellet was sol- 
ubilized with 0.1 ml of CD n&f Tris-HCl buffer (pH 6.8) con- 
taining 10% glycerol, 0.001% bromophenol blue, and 3% SDS 
(SDS sample buffer). After heating for 30 min at 6O‘C, the sus- 
pension was centrifuged for 10 min at 100,000 X g and aliquots 
of the supematant were submitted to SDS-PAGE, using the pro- 
cedure of Laemmli (31) as previously described (30). The gels 
were run, fixed, dried, and exposed to DuPont films (cronex 4) 
for l-7 days at -8O”C, using an intensifying screen. 
Data Analysis 
The LIGAND computer program (41) was used to analyze 
the binding data. The use of this program enabled models of 
receptors that best fit a given set of binding data to be selected. 
The same program was also used to present data in the form of 
Scatchard plots (53) and to compute values for receptor affinity 
(K,,) and density (B,,,) that best fit the sets of binding data for 
each rat. Statistical comparisons of all the data were carried out 
with one-way analysis of variance (ANOVA) and the Student’s 
Newman-Keuls test. Means among groups were considered sig- 
nificantly different when p < 0.05. Each individual experiment 
was performed in duplicate. 
RESULTS 
The specific binding of [‘251][Tyr”]SS to membranes from rat 
frontoparietal cortex in all rat groups bound [‘*‘I][Tyr’ ‘]SS in a 
time-dependent fashion; an apparent equilibrium was observed 
between 50 and 180 min at 30°C (data not shown). All subse- 
quent binding experiments were therefore conducted at 30°C for 
60 min. Peptide degradation was determined to rule out the pos- 
sibility of different SS-degrading activities in all the preparations 
that might have affected the interpretation of the results. Mem- 
branes from frontoparietal cortex showed a similar peptide deg- 
radation capacity, and the values varied by no more than 10% in 
all the experimental groups. 
Phenylephrine administration at a dose of 2 or 4 mg/kg pro- 
duced a significant decrease in [“‘I][Tyr”]SS binding to rat fron- 
toparietal cortex membranes compared with controls, with no 
difference detected between both doses (Table 1 and Fig. 1, left 
panel). This decrease was due to a decrease in the number of SS 
receptors as revealed by Scatchard plots of the binding data (Fig. 
1, right panel). In addition, a significant increase in the affinity 
of these receptors was observed at both of these doses (Table 1). 
No changes in the SS receptor number and affinity were observed 
at the lowest dose studied (Table 1). Therefore, subsequent stud- 
ies were carried out with 2 mg/kg, the dose frequently used by 
other investigators (5,6). 
Prazosin administration at a dose of 20 or 25 mg/kg signifi- 
cantly increased [‘251][Tyr”]SS binding to rat frontoparietal cor- 
TABLE 1 
EFFBCI OF PHENYLEPHRINE, PRAZOSIN, AND PRAZOSIN PLUS 
PHENYLEPHRINE ON X-L1 CONCENTRATION AND EQUILIBRIUM 
PARAMETERS FOR SS BINDING TO FRONTOPARIETAL 
CORTEX MEMBRANES 
SS Receptors 
Groups B mix L ss-LI 
Control 488 k 16 0.50 f 0.07 10.20 -c 0.47 
Phenylepbrine 
0.5 mgkg 456 + 35 0.57 ” 0.08 
2 mg/kg 304 t 28* 0.24 t 0.006* 9.38 t 0.70 
4 mg/kg 318” 6* 0.29 -+ O.Ol* 
Control 445237 0.52 ” 0.07 9.09 t 0.62 
Prazosin 
5 m&g 503 5 14 0.98 t O.ll* 
20 mgncg 775 -+ 82t 0.98 k O.ll* 9.01 t 0.58 
25 mgncg 748 ” 19t 1.08 2 0.11’ 
Control 490 2 22 0.43 ? 0.04 8.97 2 1.32 
Prazosin (20 mgkg) 
plus phenylephrine 
(2 mgflcg) 492 z 40 0.51 k 0.06 9.39 2 0.61 
Binding parameters were calculated from Scatchard plots by linear 
regression. Units for SSLI are ng SS per mg protein, units for k,, are nM, 
and units for B,,. are fmol of SS bound per mg of protein. The results 
are represented as the means 2 SEM of five separate experiments. 
*t Statistical comparison versus control: * p < 0.05, t p < 0.01. 
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tex membranes compared with controls, with no difference de- 
tected between both doses (Table 1 and Fig. 2, left panel). This 
increase was due to a rise in the maximum number of SS recep- 
tors as revealed by Scatchard plots of the binding data (Fig. 2, 
right panel). In addition, a significant decrease in the affinity of 
these receptors was observed at both of these doses (Table 1). 
No changes in the SS receptor number and affinity were observed 
at the lowest dose studied (Table 1). Therefore, subsequent stud- 
ies were carried out with 20 mg/kg, a dose frequently used by 
other investigators (56). Pretreatment with prazosin (20 mg/kg) 
completely blocked the changes in the number and affinity con- 
stant of SS receptors induced by phenylephrine (2 mg/kg) ad- 
ministration (Table 1 and Fig. 3). 
To assess whether phenylephrine or prazosin exert a direct 
action on SS receptors, 10m5 M phenylephrine or prazosin was 
included in the incubation medium at the time of the binding 
assay with membranes from frontoparietal cortex of normal rats. 
The addition of phenylephrine or prazosin to the incubation me- 
dium changed neither the number nor the affinity of the SS re- 
ceptors (data not shown). 
In the brain, SS binds to its specific receptors and regulates 
the AC system via guanine nucleotide binding regulatory pro- 
teins (G-proteins), which are sensitive to PTX (l&42,60). There- 
fore, we studied the PTX substrates in frontoparietal cortex after 
the treatment with phenylephrine and prazosin. PTX induced the 
incorporation of “P in a 41 kDa (G,,) and 39 kDa (G,,) protein 
under the conditions studied here (Fig. 4). Phenylephrine and 
prazosin had no effect on the PTX-catalyzed ADP ribosylation 
of Gi and G, a subunits (Fig. 4). 
To study SS-modulated AC activity, frontoparietal mem- 
branes were incubated with SS (lo-“ M), with or without FK 
(lo-’ M), a direct AC activator. No significant differences in 
basal or FK-stimulated AC activity were observed between the 
control, phenylephrine, prazosin, and prazosin plus phenyl- 
ephrine groups in frontoparietal cortex membranes (Table 2). In 
all experimental groups, SS inhibited the basal and the FK-stim- 
ulated AC activities. The treatment with phenylephrine and/or 
prazosin did not modify the capacity of SS to inhibit the basal 
0 
m-11 -10 -9 -8 0.02 0.06 0.10 
[SS]. Log M Bound, nM 
FIG. 2. Effect of in viva prazosin administration on somatostatin (SS) 
binding to frontoparietal cortex membranes. Left panel: competitive in- 
hibition of specific [‘*‘I][Tyr”]SS binding by unlabeled SS to fronto- 
parietal cortex membranes. Membranes (0.15 mg protein/ml) were in- 
cubated for 60 min at 30°C in the presence of 250 pA4 [“‘I][Tyr”]SS 
and increasing concentrations of native peptide. Points correspond to 
values for the animals in the control group (0) and prazosin-treated group 
(0). Each point is the mean + SEM of five replicate experiments. Right 
panel: Scatchard analysis of the same data. 
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FIG. 3. Effect of in viva prazosin plus phenylephrine administration on 
somatostatin (SS) binding to frontoparietal cortex membranes. Left 
panel: competitive inhibition of specific [‘“I][Tyr”]SS binding by un- 
labeled SS to frontoparietal cortex membranes. Membranes (0.15 mg 
protein/ml) were incubated for 60 min at 30°C in the presence of 250 
pM [““I][Tyr”]SS and increasing concentrations of native peptide. The 
points correspond to the values for the animals in the control group (0) 
and prazosin plus phenylephrine-treated group (0). Each point is the 
mean of five replicate experiments. Right panel: Scatchard analysis of 
the same data. 
and FK-stimulated AC activity, in comparison with the respec- 
tive control groups (Table 2). 
The administration of either phenylephrine, prazosin, and/or 
prazosin plus phenylephrine did not affect SS-LI content in fron- 
toparietal cortex in comparison with the respective control group 
(Table 1). 
DISCUSSION 
This study indicates that the administration of phenylephrine 
decreased the number of specific SS receptors in the frontopar- 
ietal cortex, while increasing receptor affinity. Pretreatment with 
the cu,-adrenergic antagonist prazosin prevented the phenyl- 
ephrine-induced changes in the binding of SS, whereas prazosin 
alone increased SS binding to its receptor. 
In previous studies, the time course of the phenylephrine and 
prazosin effect on the binding of steroid ligand to estrogen ($6) 
and progestin receptors (38), it was found that in several regions 
of the CNS of adult rats the change in the number of specific 
receptors was first detectable at 7 or 8 h after a single injection; 
at 16 h, the number of specific receptors had returned to baseline 
levels. In the present study, the treatment intervals were selected 
according to these studies. The phenylephrine and prazosin doses 
selected in the present study are similar to those used by other 
authors (5.6). 
The levels of SS-LI in the frontoparietal cortex as well as the 
binding parameters of the SS receptors in this brain area in the 
control rats were similar to those previously reported 
(16,47,51,57). Although the Scatchard plots appear to be linear, 
this is no proof for receptor homogeneity. Indeed, it has been 
demonstrated for many years that SS binding in rat brain is het- 
erogeneous (43,53). It has been demonstrated recently that there 
are five cloned receptors expressed in the brain and that all have 
a similar high affinity for SS (3,10). Thus, a linear Scatchard plot 
indicates only that the labeled sites have a similar affinity for the 
radioligand used. 
The stimulation of (Y, adrenoceptors primarily stimulates the 
phospholipase C-catalyzed breakdown of phosphoinositides, 
leading to the generation of inositol triphosphate and diacylgly- 
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Phenylephrine Prazosin 
Control Treabd Contml Trehd 
q- 41 KDa 
d- 39 KDa 
Fbrtussis 
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FIG. 4. Autoradiography of [“P]ADP-ribosyIated brain membrane proteins. Fronto- 
parietal cortex membranes (0.8 mg protein/ml) from controls, phenylephrine-treated, 
and prazosin-treated rats were incubated for 30 min at 30°C in the presence of 
[“P]NAD+, with (+) or without (-) pertussis toxin (16 &ml). This experiment is 
representative of six others. 
cerol (38). A series of recent reports has suggested that diacyl- 
glycerol derived from phosphatidylinositol breakdown is directly 
involved in the transmemb:rane control of protein phosphoryla- 
tion through the activation of protein kinase C (43). It is tempting 
to speculate that the decrease in labeled SS binding induced by 
activation of a, adrenoceptors might be a consequence of the 
activation of protein kinase C by diacylglycerol. In this regard, 
Matozaki et al. (36) have re.ported that diacylglycerol modulates 
SS binding to its receptors on rat pancreatic acinar cell mem- 
branes. 
In our experiments, SS inhibited frontoparietal cortex AC ac- 
tivity in rats, a finding that is in agreement with the literature 
(35,42,54). A relatively high concentration of SS (10e4 h4) is 
required to produce inhibition. Other authors (4,18,42,54) used 
the same concentration in their studies on SS inhibition of human 
and rat brain AC. There is evidence suggesting that the effect of 
SS on AC activity is receptlor mediated, rather than being a non- 
specific inhibitory effect. 
The SS concentration necessary to elicit the maximal inhibi- 
tion of AC activity was about threefold that necessary to displace 
[“‘I][Tyr”]SS binding to its receptors. This apparent discrepancy 
may be explained observing that the PTX-sensitive G-proteins 
can modulate the affinity of SS receptors and/or the receptor cou- 
pling to the transduction system (AC among others). In this re- 
spect, Enjalbert et al. (14) imd Koch and Schonbrunn (28) have 
shown that GTP-induced mobilization of the G-protein reduces 
SS receptor affinity of the neuropeptide in cerebral cortical cells 
and in GH,C, pituitary cell clones. 
The changes in the number of SS receptors following ag- 
onist or antagonist cu,-adrenoceptor administration was not ac- 
companied by a corresponding modification in SS-inhibited 
AC activity. Some of these receptors are coupled by PTX- 
sensitive guanine nucleotide binding proteins (G-proteins) to 
a variety of cellular effector systems and mediate the inhibi- 
tion by SS of AC (48,54) and voltage-sensitive Ca2+ channel 
activity (63), as well as stimulation of K+ channel activity 
(62). Other cellular actions of SS, including its antiprolifera- 
tive effects (61) and regulation of Na+/H+ exchange (2), 
appear to be mediated by PTX-insensitive mechanisms, indi- 
cating heterogeneity of receptor-effector interactions. There- 
fore, it is possible that the SS receptors modified by the (Y,- 
adrenergic system have not been functionally coupled to 
guanine nucleotide regulatory protein G,, and may represent 
spare receptors, or a subpopulation of SS receptors that are 
coupled to an alternative second messenger system. 
An inconsistency between changes in receptors and signal 
transduction is not unprecedented. For example, chronic ex- 
posure of primary cultures of mouse cortical neurons to the 
muscarinic antagonist atropine has been shown to increase the 
density of muscarinic receptors while decreasing carbachol- 
stimulated phosphoinositide hydrolysis (56). Alternatively, 
the lack of correlation between the magnitude of SS inhibition 
TABLE 2 
EFFECT OF SS AND FK ON BRAIN AC ACTIVITY (pmol cAMP/min/mg protein) 
Phenylephrine (n = 5) Prazosin (n = 5) 
Control Treated 
Basal activity 288 2 6 261 2 15 
Basal activity + 10m4 M SS 215 ? 10 207 2 13 
SS inhibition of basal activity (%) 26 3- 3 23 2 2 
+ lO_‘MFK 781 2 6 643 2 25 
Fold FK stimulation over basal 2.7 2 0.1 2.4 + 0.1 
10m5 M FK + lO-4 M SS 587 5 9 473 2 23 
SS inhibition of PK stimulation (%J) 25 z 2 26 ? 2 
Control Treated 
323 2 I 331 2 6 
239 2 7 244 2 12 
26 2 1 26 ? 3 
925 + 11 922 2 19 
2.9 t 0.1 2.8 2 0.1 
648 % 43 665 + 31 
30 k 4 28 2 4 
Prazosin Plus Phenylephrine (n = 5) 
Contrcll Treated 
321 2 4 322 + 12 
254 2 5 254 2 11 
21 2 2 21 2 1 
930 ? 35 939 + 89 
2.9 + 0.1 2.9 2 0.1 
691 2 32 696 k 28 
26 2 1 26 2 4 
Experiments were performed as described in the Method section. Values represent the mean 2 SEM of the determinations performed. 
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of AC and the density of [‘251][Tyr”]SS receptors seems to 
suggest the coupling of SS receptors to multiple signal trans- 
duction mechanisms or may be related to factors such as mul- 
tiple and spare receptors sites. Of relevance to this observation 
is a recent report demonstrating no apparent match between 
the level of SS receptor sites and the magnitude of SS inhi- 
bition of AC activity in the frontal cortex of a group of Al- 
zheimer’s disease patients (4). 
The functional significance of these findings remains to be 
clarified. Because SS and its receptors are present in the fron- 
toparietal cortex and there are studies indicating that SS causes 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
general tonic-clonic seizures when applied to rats (23), it is 
tempting to speculate that the anticonvulsant activity by stim- 
ulation of (Y, adrenoceptors (33.39) may, at least in part, de- 
pend on a decrease in the number of SS receptors. 
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